Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Vitamin D Receptor Start Codon Polymorphism (FokI) and Prostate Cancer Progression

Yue Xu, Atsuko Shibata, John E. McNeal, Thomas A. Stamey, David Feldman and Donna M. Peehl
Yue Xu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atsuko Shibata
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John E. McNeal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas A. Stamey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Feldman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donna M. Peehl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2003
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

  • Table 1

    Mean ± SD of baseline characteristics of the 191 study subjects by the VDR FokI genotype

    VariableVDR FokI genotypePa
    FFFfff
    No. of subjects (%)78 (41%)73 (38%)40 (21%)
    Age at surgery (yrs)64.8 ± 6.865.2 ± 6.563.2 ± 6.20.28
    % Gleason grade 4/542.8 ± 30.043.8 ± 30.230.3 ± 28.60.05b
    Index cancer volume (cc)5.2 ± 5.35.3 ± 5.75.7 ± 6.00.88
    Preoperative serum PSA (ng/ml)24.5 ± 39.519.7 ± 23.218.5 ± 14.10.49
    • a By ANOVA.

    • b P = 0.015 by t test when the FF and Ff genotypes were combined and compared with the ff genotype.

  • Table 2

    Results of Cox proportional hazards model analysis for PSA failure

    Covariates adjusted foraVDR FokI genotypeb
    Ffff
    HR95% CIHR95% CI
    Age1.020.66–1.580.760.44–1.32
    Age, Gleason grade, cancer, volume, and preoperative serum PSA1.070.68–1.691.030.58–1.85
    • a The following categories were used: age at surgery in years (<60, 60–64, 65–69, 70+); % Gleason grade 4/5 (<15%, 15–34%, 35–69%, ≥70%); cancer volume in cc (<2.00, 2.00–3.25, 3.26–6.68, ≥6.69); and preoperative serum PSA level in ng/ml (<9.1, 9.1–14.8, 14.9–24.9, ≥25.0).

    • b The FF genotype was considered as a reference category.

PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 12 (1)
January 2003
Volume 12, Issue 1
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Vitamin D Receptor Start Codon Polymorphism (FokI) and Prostate Cancer Progression
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Vitamin D Receptor Start Codon Polymorphism (FokI) and Prostate Cancer Progression
Yue Xu, Atsuko Shibata, John E. McNeal, Thomas A. Stamey, David Feldman and Donna M. Peehl
Cancer Epidemiol Biomarkers Prev January 1 2003 (12) (1) 23-27;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Vitamin D Receptor Start Codon Polymorphism (FokI) and Prostate Cancer Progression
Yue Xu, Atsuko Shibata, John E. McNeal, Thomas A. Stamey, David Feldman and Donna M. Peehl
Cancer Epidemiol Biomarkers Prev January 1 2003 (12) (1) 23-27;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Urinary Melatonin in Relation to Breast Cancer Risk
  • Endometrial Cancer and Ovarian Cancer Cross-Cancer GWAS
  • Risk Factors of Subsequent CNS Tumor after Pediatric Cancer
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement